Population scale proteomics accelerates the search for effective new drug targets

In this video, Dr. Chris Whelan, Chair and Principal Investigator of the UK Biobank – Pharma Proteomics Project, discusses how data from the UK Biobank – Pharma Proteomics Project has revealed new insights into associations between gene variants and protein concentrations enabling new causal biomarkers for diseases to be identified as well as new drug targets with higher probabilities of success. Dr. Whelan explains how Proximity Extension Assay (PEA) technology from Olink was used to quantify these protein concentrations using innovative dual recognition, DNA-coupled methodology.